Hyperfine, Inc. Class A HYPR 深 滬
等待開盤 08-01 09:30:00 美东时间
0.9358
+0.008
+0.82%
華盛通- 最 高0.9603
- 今 開0.9326
- 成交量 38.36万股
- 最 低 0.92
- 昨 收 0.9282
- 總市值 9289.72万
- 52周最高 2.22
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 0.85
- 委 比 -94.80%
- 總股本 9927.03万
- 歷史最高 16.61
- 量 比 0.70
- 振 幅 4.34%
- 歷史最低 0.5327
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Hyperfine宣布在欧洲推出下一代Swoop系统
Hyperfine（纳斯达克代码：HYPR）近日宣布，正式在欧洲市场推出下一代Swoop便携式MRI系统(磁共振成像系统)，这是公司国际化商业拓展战略的重要...
07-01 23:41
Hyperfine Presents PRIME Study Results At SAEM 2026 Annual Meeting
Prospective randomized ED study shows rapid bedside imaging, detection of critical neurological findings, and potential workflow efficiency benefits with portable MRI
05-22 20:17
Hyperfine targets $20M-$22M 2026 revenue while maintaining 50%-55% gross margin
Earnings Call Insights: Hyperfine, Inc. (HYPR) Q1 2026 Management View CEO Maria Sainz framed Q1 as execution against both growth and cost control, saying, "The first quarter was a strong start to 202...
05-13 11:41
Hyperfine Q1 2026 Earnings Call Transcript
Hyperfine (NASDAQ:HYPR) reported first-quarter financial results on Tuesday. Th...
05-13 05:24
Hyperfine Files Prospectus For Resale Of 1,083,335 Shares Of Class A Common Stock By Selling Securityholders
HYPERFINE, INC.Up to 1,083,335 Shares of Class A Common StockThis prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the "Selling Securityholders") of up to
05-13 04:58
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
BTIG Initiates Coverage On Hyperfine with Buy Rating, Announces Price Target of $2
BTIG analyst Marie Thibault initiates coverage on Hyperfine (NASDAQ:HYPR) with a Buy rating and announces Price Target of $2.
04-29 18:52
Hyperfine Receives CE Marking And UK Conformity Assessment Approval For Both Next-Gen Swoop System And Latest Advancement In Optive AI Software
This milestone unlocks Hyperfine's most significant technology innovations to date for clinicians and patients across Europe and the United Kingdom, delivering a transformative leap in image quality and a major expansion
04-09 20:18
